Semaglutide peptide tablets: what the clinical evidence actually shows

What the OASIS 4 trial found, and how to read the numbers honestly

The pivotal trial behind the MHRA approval was OASIS 4, a phase 3 study involving 307 adults living with obesity or overweight plus at least one weight-related condition, none of whom had type 2 diabetes. Over 64 weeks, participants taking the 25 mg oral maintenance dose alongside lifestyle changes lost an average of 13.6% of their body weight, compared with 2.4% in the placebo group. Among those who stayed fully adherent to treatment throughout, the average reached around 16.6%, roughly 17%. That distinction matters: the 17% figure applies specifically to the adherent subgroup, not to everyone who started the trial. Both numbers are meaningful, but quoting the higher one without that context gives a misleading picture.

Gastrointestinal side effects were the most common finding: 74% of participants on oral semaglutide reported them, versus 42% on placebo. Most were mild to moderate and settled over time, particularly in the weeks following a dose increase. Nausea was the most frequently reported symptom. The MHRA's announcement of the approval is publicly available and gives a clear account of what the regulator assessed before granting the licence.

One misconception worth addressing gently: some people assume a tablet must be weaker than an injection because it's less invasive. If you want to understand exactly how the oral form works, our page on the semaglutide tablet explains how the semaglutide peptide is identical in both formulations and how the SNAC co-formulation addresses the absorption challenge rather than the molecule itself. The trial results reflect that the tablet genuinely works, the absorption engineering was the scientific challenge, not the molecule itself.

How oral semaglutide sits alongside the injection, and where Rybelsus fits in

Wegovy tablets are not the only oral semaglutide product on the market, and the distinction between them is clinically important. Rybelsus (also oral semaglutide, also made by Novo Nordisk) is licensed solely for type 2 diabetes at doses of 3 mg, 7 mg and 14 mg. Those three strengths are not steps on the Wegovy weight-loss ladder and should never be used interchangeably with it. If you've come across references to semaglutide 7 mg tablets in a weight-loss context, that is a Rybelsus dose, and Rybelsus is not licensed for weight management. The transition from Rybelsus to Wegovy is a separate clinical question entirely, one that a prescriber needs to assess individually.

The Wegovy injection, by contrast, reaches a maintenance dose of 2.4 mg weekly, with a higher 7.2 mg dose approved by the MHRA in January 2026 for patients with BMI ≥ 30. The tablet's 25 mg maintenance dose looks much larger numerically, but the comparison isn't straightforward: oral bioavailability of semaglutide is far lower than subcutaneous, so the doses aren't equivalent in the way milligrams of a conventional drug might be. A fuller look at how the formats compare is available on the Wegovy pill overview page.

Patients who are already established on the 2.4 mg weekly injection may move to the 25 mg tablet directly, bypassing the titration schedule, but only following a clinical assessment, not as a self-managed switch. The NHS confirms that Wegovy tablets are not currently available on the NHS; access at launch is through private prescription only.

Who the tablets are licensed for, and what the prescriber looks at

The licence covers adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. Lower thresholds (typically 2.5 kg/m² less) apply for South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds under UK guidance. Meeting the BMI figure is a starting point, not an approval: a prescriber reviews your medical history, current medicines and other factors before any prescription is issued.

The tablets are not suitable during pregnancy, breastfeeding or while trying to conceive. They are not licensed for use in under-18s. Anyone taking oral contraceptives alongside tirzepatide (a different weight-loss medicine) should note specific guidance on pill absorption, for semaglutide, current NHS evidence does not indicate the same interaction, though this is worth raising at consultation. You can read more about oral semaglutide for weight loss in the context of how the medicine is taken and managed. The NHS medicines page for semaglutide covers side effects and safety information in plain language and is worth reading before starting any treatment.

For a broader view of licensed weight-loss medicines available in the UK, the weight-loss treatment overview sets out how the options compare. If you have questions about whether these tablets are right for your situation, the most direct route is a clinical conversation rather than more reading.

Taking the tablet correctly, the detail that changes how well it works

Oral semaglutide is absorbed through a narrow window in the stomach wall, and the conditions around taking it directly affect how much reaches your bloodstream. The SNAC co-formulation works by transiently raising the local pH at the gastric mucosa, which is why timing is so specific. Our page on semaglutide tablets sets out the full routine, including why the tablet goes first thing in the morning before anything else, with no more than about 120 ml of plain water. Coffee, a small breakfast, even another tablet taken too close can materially reduce absorption. The 30-minute gap before eating or drinking anything else isn't a suggestion, it's a pharmacological requirement built into how the formulation was designed and tested.

Because no refrigeration is required, the tablets are considerably easier to manage when travelling than the injection. There's no cold chain to maintain, no sharps disposal to arrange, no pen to transport carefully. That's a genuine practical advantage for some patients, and one that the OASIS 4 trial conditions didn't specifically test but that real-world adherence tends to favour. Storage details, including the precise temperature range and any light-exposure precautions, are set out in the patient information leaflet that comes with each pack, the eMC's product information is the reference document if you want to read ahead. Speak to our prescribers if you'd like to understand whether the tablets or the injection suit your circumstances better: a free consultation at nume's treatment page is the starting point.